-

Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2022 financial results will be released on Thursday, October 27 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2022 financial results and will provide a business update.

A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, Investors
investor_relations@gilead.com

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English
Hashtags
#Earnings
#GILD
#GileadInvestorRelations
#GileadSciences
#QuarterlyResults
#Results

Contacts

Jacquie Ross, Investors
investor_relations@gilead.com

Social Media Profiles
Gilead Sciences Facebook
Gilead Sciences Instagram
Gilead Sciences LinkedIn
Gilead Sciences YouTube
More News From Gilead Sciences, Inc.

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously admi...

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

FOSTER CITY, Calif.--(BUSINESS WIRE)--GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US...

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The n...
Back to Newsroom